Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I multiple-dose study of IVA337 in healthy Japanese adults
jRCT2031240629Phase 1Completed
- Sponsor
- Hepalys Pharma
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of lanifibranor in metabolic dysfunction-associated steatohepatitis (MASH) (6 cohorts), sponsored by Hepalys Pharma. Primary endpoints: Safety and tolerability of IVA337, Pharmacokinetics of IVA337 and 1 more. Started Feb 2025; status: completed.
02
Drugs
lanifibranor
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on jRCT2031240629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240629.